Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more
Shenyang Xingqi Pharmaceutical Co Ltd (300573) - Total Liabilities
Latest total liabilities as of September 2025: CN¥562.18 Million CNY
Based on the latest financial reports, Shenyang Xingqi Pharmaceutical Co Ltd (300573) has total liabilities worth CN¥562.18 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenyang Xingqi Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shenyang Xingqi Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenyang Xingqi Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The GEO Group Inc
F:GEG
|
Germany | €2.29 Billion |
|
Shenzhen Honor Electronic Co Ltd
SHE:300870
|
China | CN¥2.93 Billion |
|
Sugi Holdings Co.Ltd
PINK:SGIPF
|
USA | $334.72 Billion |
|
Pylon Technologies Co. Ltd. A
SHG:688063
|
China | CN¥3.62 Billion |
|
Songcheng Performance Develop
SHE:300144
|
China | CN¥1.46 Billion |
|
Aerospace Hi-Tech Holding Group Co Ltd
SHE:000901
|
China | CN¥2.71 Billion |
|
Sinbon Electronics Co Ltd
TW:3023
|
Taiwan | NT$15.50 Billion |
|
RXO Inc.
NYSE:RXO
|
USA | $1.74 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Shenyang Xingqi Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenyang Xingqi Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥534.48 Million | +60.06% |
| 2023-12-31 | CN¥333.92 Million | +44.79% |
| 2022-12-31 | CN¥230.63 Million | -32.63% |
| 2021-12-31 | CN¥342.35 Million | +26.03% |
| 2020-12-31 | CN¥271.64 Million | -2.10% |
| 2019-12-31 | CN¥277.46 Million | +80.30% |
| 2018-12-31 | CN¥153.89 Million | +25.02% |
| 2017-12-31 | CN¥123.09 Million | -38.60% |
| 2016-12-31 | CN¥200.47 Million | -23.24% |
| 2015-12-31 | CN¥261.15 Million | -13.84% |
| 2014-12-31 | CN¥303.09 Million | +31.55% |
| 2013-12-31 | CN¥230.41 Million | +80.97% |
| 2012-12-31 | CN¥127.32 Million | +509.68% |
| 2011-12-31 | CN¥20.88 Million | -- |